Neurofilaments as biomarkers in multiple sclerosis

Area of Science:

• Neurology
• Biomarker Discovery
• Neuroimmunology

Background:

• Neurodegeneration correlates with multiple sclerosis (MS) progression, necessitating sensitive biological biomarkers.
• Cerebrospinal fluid (CSF) neurofilament protein subunits are explored as potential MS biomarkers.

Purpose of the Study:

• To evaluate the potential of neurofilament light (NfL) and heavy (NfH) subunits as CSF biomarkers in MS.
• To assess the prognostic value of NfL and NfH in predicting conversion from clinically isolated syndrome (CIS) to definite MS and disease progression.

Main Methods:

• Analysis of neurofilament light, heavy, and intermediate subunits in cerebrospinal fluid (CSF).
• Review of recent studies examining neurofilament levels in relation to MS progression, treatment, and disability.

Main Results:

• Neurofilament light (NfL) subunit may indicate acute axonal damage and predict conversion from clinically isolated syndrome (CIS) to MS.
• Neurofilament heavy (NfH) subunit might reflect chronic damage, predicting disease progression and disability.
• Altered NfL and NfH levels in response to treatments suggest potential for monitoring therapeutic effects.

Conclusions:

• NfL and NfH show potential as prognostic biomarkers for MS, reflecting different aspects of neurodegeneration.
• Neurofilament subunits may be valuable in monitoring treatment efficacy and side effects in MS patients.
• Standardization and validation of assays are crucial for clinical implementation and predictive value confirmation.